Bridge Biotherapeutics Inc., a biotech company headquartered in Seongnam, South Korea, has signed a license agreement with Daewoong Pharmaceutical Co., Ltd. for development of BBT-401, the first anti-Pellino-1 compound currently under development for ulcerative colitis (UC) treatment.   Under the license and collaboration, the companies will co-develop a new clinical-stage drug candidate for the treatment of patients with UC. Bridge Biotherapeutics will receive as much as $40 million for an up...